Mednet Logo
SpecialtiesRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

How would you approach managing severe, functionally disabling steroid induced edema that is refractory to treatment with chlorthalidone or bumetanide?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Texas Christian University

This is a difficult issue - I'm assuming the patient is unable to taper steroids at this time. The edema results from the mineralocorticoid activity of the steroid, so attempting to change to a low or negligible mineralocorticoid corticosteroid may be helpful if possible - dexamethasone, betamethaso...

What was the rationale for abrupt discontinuation of etanercept rather than gradual tapering in the SEAM-RA trial?

2 Answers

Mednet Member
Mednet Member
Rheumatology · University of Alabama

The main goal of this trial was to get RA patients off of therapy and to see whether they would flare or maintain remission. We didn’t expect that the ultimate likelihood of success or failure was going to be primarily related to how long it took to do that. While a gradual withdrawal of the drug ma...

What is the recommended fungal workup in an immunocompromised patient after 5 days of persistent fever?

1
3 Answers

Mednet Member
Mednet Member
Infectious Disease · University of Texas Southwestern Medical School

For any patient with fevers, I focus significantly on any symptoms that a patient might have, like headache, diarrhea, and sinus symptoms, and work up a differential diagnosis based on possible pathogens in this area. If I am not finding anything, I would obtain a CT chest/abd/pelvis, as both invasi...

How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?

3
6 Answers

Mednet Member
Mednet Member
Rheumatology · UTMB Health

I would certainly treat the ITP with hematology involvement if necessary but would continue to monitor for lupus or similar CTDs. I have seen patients present with an ITP-like picture for years before lupus declared itself eventually. It may take years. I would also check a UA for proteinuria. This ...

In a patient with statin induced immune-mediated necrotizing myopathy (+ anti-HMGCR antibodies), would you consider brepocitinib in the treatment algorithm?

1 Answers

Mednet Member
Mednet Member
Rheumatology · The University of Texas Health Science Center at Houston (UTHealth)

Unlike dermatomyositis, anti-HMGCR IMNM generally lacks a strong interferon signature. Therefore, the biologic rationale for JAK inhibition is less compelling, and I would not routinely consider brepocitinib in this setting.

What is the most appropriate next step in management for a patient with dermatomyositis who is maintained on methotrexate 25 mg weekly but develops disease flare when prednisone is tapered below 10 mg daily and is unable to receive IVIG?

2
3 Answers

Mednet Member
Mednet Member
Rheumatology · The University of Texas Health Science Center at Houston (UTHealth)

The fact that the patient cannot taper prednisone below 10 mg indicates that methotrexate alone, while has some effect, is not sufficient to control the disease. There are several options, depending on the severity of each organ involvement. Since the joints are affected, I would favor an agent that...

How do you approach prescribing analgesics for osteoarthritis related pain in patients with comorbidities, particularly given new evidence that even acetaminophen is associated with increased risk of GI complications (bleeding, peptic ulcer disease), heart failure and CKD?

3
3 Answers

Mednet Member
Mednet Member
Rheumatology · University of Kansas

Acetaminophen is still preferred, but at 3,000 mg or less per day. The next consideration is a COX-2 specific inhibitor, such as celebrex. Narcotics and steroids play no role in management of osteoarthritis.

When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?

3
2 Answers

Mednet Member
Mednet Member
Rheumatology · Icahn School of Medicine at Mount Sinai

Some background: In patients discontinuing denosumab without subsequent antiresorptive therapy, BMD rapidly reverts back to baseline with an elevation in vertebral fracture risk (with an enhanced risk of multiple vertebral fractures). Thus, sequential treatment regimens following denosumab have been...

How do you counsel patients on the potential benefits of nerandomilast for PPF?

3 Answers

Mednet Member
Mednet Member
Rheumatology · University of Washington

Nerandomilast is an inhibitor of phosphodiesterase 4 (PDE4), which leads to elevated intracellular cAMP, which reduces the expression of profibrotic cytokines and growth factors. It has both antifibrotic and immunomodulatory activity and may be useful in active inflammatory ILD based on these charac...

Are there adverse consequences of suppressing serum urate levels too much?

7
2 Answers

Mednet Member
Mednet Member
Rheumatology · Ohio State Dodd Rehabilitation Hospital

It's an interesting question. I personally do not have a lower limit that I have in mind per se, and frankly rarely see anything less than 3 in any of my patients. But I would consider 2-3 being a range which could be deemed low and potentially an issue long term in brain health and because of its n...